

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

**FOR IMMEDIATE RELEASE:
February 12, 2021**

Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product License for SmoothX; Radiographic Barium Contrast Suspension

Calgary, Alberta: February 12, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for SmoothX. SmoothX is a barium radiographic contrast suspension that is specifically formulated for computed tomography procedures (CT Scans). This approval authorizes the sale of SmoothX for use in radiology procedures in Canada. SmoothX is specifically designed for use on CT Scans of the abdomen and gastrointestinal tract in both adults and pediatric patients.

Voyageur has four additional barium radiographic contrast Products that are currently under review by Health Canada and we expect product licences to be imminent.

“Voyageur’s business plan has always been to launch Barium Contrast Radiographic Suspension products into the Canadian marketplace initially, then pursue other markets. This approval is the critical milestone to allow our company to transition to a cash flowing pharmaceutical company” reports Brent Willis, Voyageur’s CEO.

Voyageur has an intricate plan to advance through the start-up phase of formulating, final testing of product and then manufacturing. This is expected to lead to full production manufacturing, sales and distribution of barium contrast products nationally in the near term.

About Voyageur

Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium, iodine radio-contrast products and fullerene-based pharmaceutical products.

Voyageur’s goal is to initially generate the positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and in India. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing.

Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radio-contrast medical field, by controlling all primary input costs under the motto of:

"From the Earth to the Bottle"

www.voyageurpharmaceuticals.ca

For Further Media Information or to set up an interview, please contact:

Brent Willis
President & CEO
E brent@vpharma.ca

Ron Love
CFO
T 403.818.6086
E ronl@vpharma.ca

Forward Looking Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to timing for manufacturing and sales of SmoothX and the Company's ability to obtain necessary approvals from Health Canada for the four additional barium radiographic contrast products. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Reader Advisory

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.